Computed Tomography trials for Breast cancer

All Computed Tomography trials · All Breast cancer trials

Phase breakdown

Recruiting trials studying Computed Tomography for Breast cancer

• A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer
  NCT07078604 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer
  NCT04521764 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
  NCT07112053 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer
  NCT06525766 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer
  NCT06860815 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy
  NCT05770531 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
  NCT06179303 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
  NCT06026657 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
  NCT04119024 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations
• High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
  NCT06492759 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
  NCT06518057 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
  NCT06635980 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer
  NCT06130826 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
  NCT05098210 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
  NCT05269381 · Phase: Phase 1, Phase 2 · Ages: 16 Years and older · Sex: All (male and female) · 2 locations
• Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy
  NCT06055881 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female · 2 locations
• Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer
  NCT05741164 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 2 locations
• Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
  NCT03604315 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Female · 1 location
• Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer
  NCT06260033 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer
  NCT06434064 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
  NCT05564377 · Phase: Phase 2 · Ages: No age limits stated · Sex: All (male and female) · 482 locations
• Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
  NCT06500455 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 270 locations
• Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
  NCT06500481 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 58 locations
• Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
  NCT07391774 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 177 locations
• Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
  NCT05422794 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
  NCT03606967 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
  NCT05111561 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• [18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer
  NCT06502691 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many trials study Computed Tomography for Breast cancer?

28 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.